9265 related articles for article (PubMed ID: 21061768)
1. CTLA4-induced splenomegaly and a review of the literature pertaining to autoimmune complications of therapy.
Ezra N; Goltche NB; Hakimian S; Afari A
J Drugs Dermatol; 2010 Nov; 9(11):1432-6. PubMed ID: 21061768
[TBL] [Abstract][Full Text] [Related]
2. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
3. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of metastatic melanoma with CTLA4 antibodies].
Hafner C
Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523
[No Abstract] [Full Text] [Related]
6. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
7. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Kaehler KC; Egberts F; Lorigan P; Hauschild A
Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
Straatsma BR; Nusinowitz S; Young TA; Gordon LK; Chun MW; Rosen C; Seja E; Economou JS; Glaspy JA; Bozon V; Gomez-Navarro J; Ribas A
Am J Ophthalmol; 2007 Jun; 143(6):958-969. PubMed ID: 17434437
[TBL] [Abstract][Full Text] [Related]
11. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
[TBL] [Abstract][Full Text] [Related]
12. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J Immunother; ; . PubMed ID: 16224277
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
